From biomarkers to medical tests: the changing landscape of test evaluation.
Regulators and healthcare payers are increasingly demanding evidence that biomarkers deliver patient benefits to justify their use in clinical practice. Laboratory professionals need to be familiar with these evidence requirements to better engage in biomarker research and decisions about their appropriate use. This paper by a multidisciplinary group of the European Federation of Clinical Chemistry and Laboratory Medicine describes the pathway of a laboratory assay measuring a biomarker to becoming a medically useful test. We define the key terms, principles and components of the test evaluation process. Unlike previously described linearly staged models, we illustrate how the essential components of analytical and clinical performances, clinical and cost-effectiveness and the broader impact of testing assemble in a dynamic cycle. We highlight the importance of defining clinical goals and how the intended application of the biomarker in the clinical pathway should drive each component of test evaluation. This approach emphasizes the interaction of the different components, and that clinical effectiveness data should be fed back to refine analytical and clinical performances to achieve improved outcomes. The framework aims to support the understanding of key stakeholders. The laboratory profession needs to strengthen collaboration with industry and experts in evidence-based medicine, regulatory bodies and policy makers for better decisions about the use of new and existing medical tests.
SEALS Department of Clinical Chemistry, Prince of Wales Hospital and School of Medical Sciences, University of New South Wales, Australia; Screening and Test Evaluation Program, School of Public Health, University of Sydney, Australia. Electronic address: rita.horvath@sesiahs.health.nsw.gov.au.
Andrea R
AR
Horvath
Sarah J
SJ
Lord
Andrew
A
StJohn
Sverre
S
Sandberg
Christa M
CM
Cobbaert
Stefan
S
Lorenz
Phillip J
PJ
Monaghan
Wilma D J
WD
Verhagen-Kamerbeek
Christoph
C
Ebert
Patrick M M
PM
Bossuyt
D015415:Biomarkers / Q000032:analysis; D019411:Clinical Laboratory Techniques / Q000191:economics / Q000379:methods* / Q000639:trends*; D019317:Evidence-Based Medicine; D006801:Humans; D016896:Treatment Outcome
D015415:Biomarkers
ACR; ACS; AMI; B-type natriuretic peptide; BNP; Biomarker; C-reactive protein; CE; CK-MB; CRP; Clinical effectiveness; Conformité Européenne; EFLM; EU; European Federation of Clinical Chemistry and Laboratory Medicine (formerly abbreviated as EFCC); European Union; Evidence-based laboratory medicine; FDA; Food and Drug Administration; HbA(1c); Hemoglobin A(1c); IFCC; INR; IVD; International Federation of Clinical Chemistry and Laboratory Medicine; Medical test; NGSP; NHS; NICE; National Glycohemoglobin Standardization Program; National Health Service in the United Kingdom; National Institute for Health and Care Excellence; PoCT; RCT; acute coronary syndrome; acute myocardial infarction; albumin:creatinine ratio; cTn; cardiac Troponin; creatine kinase MB isoform; high sensitivity cardiac Troponin; hs-cTn; in vitro diagnostics; international normalized ratio; point of care testing; randomized controlled trial